Navigation Links
International Isotopes Inc. Announces Year End Financial Results
Date:3/28/2008

Company Shows A 5% Increase In Total Revenue To $4.7 Million

IDAHO FALLS, Idaho, March 28 /PRNewswire-FirstCall/ -- International Isotopes Inc. (OTC Bulletin Board: INIS) announces the financial results for fiscal year ended December 31, 2007.

Total revenue in 2007 was $4,690,588 compared to $4,469,538 in 2006, which represents an increase of $221,050 or 5%. The overall increase in revenue was affected to a great extent by an 11% reduction in Cobalt product revenue in 2007 compared to 2006 that was due primarily to normal cyclical fluctuations in bulk cobalt sales. These fluctuations cause large variations in the revenue that impacts period to period comparisons. Excluding cobalt product sales, revenue for the year ended December 31, 2007 was $3,625,861 as compared to $3,277,514 for the same period in 2006, which represents an increase of $348,347 or 11%. Because of the significant impact of the timing of cobalt product sales, management believes excluding sales of cobalt products from the period comparisons of revenue provides useful information to investors and may provide a more accurate projection of our actual revenue growth trends. Please refer to the tables below for a further analysis of this measure and a year to year comparison of the individual business segments.

Business Segment Area 2006 2007 Percent Change

Nuclear Medicine Products $1,684,727 $1,819,049 8%

Radiochemical Products $844,014 $1,062,477 26%

Cobalt Products $1,192,024 $1,064,727 (11%)

Radiological Services $641,411 $590,160 (8%)

Total Revenue $4,469,538 $4,690,588 5%

Total Revenue Excluding

Cobalt Products $3,277,514 $3,625,861 11%

Cost of revenue for 2007, was $2,660,781 compared to $2,462,715 in 2006, an increase of $198,066 or 8%. Gross profit for 2007, was $2,029,807 or 43% as compared to $2,006,823 or 45% in 2006. The increase in cost of goods sold was attributable to the rapidly escalating price of lead, increased manufacturing costs due some changes in manufacturing processes, and increases in oil prices which have impacted packaging product materials. We have several measures in place to compensate for these increased expenses in the coming year.

Total operating costs and expenses for 2007, were $3,645,549 as compared to $2,871,295 in 2006, an increase of $774,254 or 27%. The increase was equally attributable to four contributing factors namely, FEP production supplies and equipment depreciation; wages attributable to the cost of stock options; increased legal and auditing services related to our private placement as well as other corporate actions, and costs associated with the Phase I research and development grant from the National Science Foundation.

Net Loss was $1,719,055 in 2007 compared to a net loss of $1,037,312 in 2006. The $681,743 increase in net loss was attributable to the factors discussed above.

Steve Laflin, President and CEO said, "We made several significant advances in our business in 2007. The following is a list of some of the more significant accomplishments.

-- "We increased revenues in our major business segments and continued to

diversify our customer base.

-- "We completed a private placement with Firebird Global Master Fund II,

Ltd. affiliated with New York-based Firebird Management LLC, which has

made considerable investments in the areas of uranium, fluorine, and

germanium. This investment provides us with a stronger financial

platform from which we can further develop our products and future

business potential associated with FEP.

-- "We acquired a 6% ownership position in RadQual, a major customer that

represents sales totaling 58% of our gross revenue in 2007. This

purchase agreement provides us with an option to acquire up to a total

of 20% in RadQual through December 31, 2008. This purchase agreement

is our first step towards acquiring even greater control of our

contract manufacturing future in the Nuclear Medicine products segment.

-- "We have continued to add new cobalt products, including a several

models of sealed source capsules, and expanded sales agreements with

new international customers.

-- "We were awarded several contracts by the Department of Energy to

assist with efforts related to the Orphan Source Recovery Project for

on site recovery and packaging of orphaned radioactive materials.

-- "We received a grant to complete Phase I research into use of germanium

tetrafluoride as a fluorinating agent for production of hydro

fluorocarbon from the National Science Foundation.

-- "We entered into an agreement with Alpha Omega Services to become its

exclusive worldwide distributor of its new family of type B radioactive

material packages.

-- "We were recognized by the Occupational Safety and Health

Administration (OSHA), through their Safety and Health Award

Recognition Program (SHARP), as just the seventh business in Idaho, and

a select few nationwide, to have demonstrated an exemplary safety and

health management program and flawless worker safety record.

-- "We expanded our management team to include a new Chief Financial

Officer to support the continued growth of our existing business and

expansion into new business areas," concluded Steve Laflin

Laflin also identified the following goals and objectives for the Company in 2008 based upon the investments made in the Company's production facilities and the expanded products developed during 2007:

-- To begin commercial production and sale of germanium tetrafluoride

using our FEP gas production plant and explore larger scale production

of other FEP gasses such as silicon tetrafluoride or boron trifluoride.

-- To pursue additional opportunities for various source recovery and

recycle programs expected to be funded through the federal government

and to which we are uniquely suited to provide services.

-- Continue to advertise and promote the use of International Isotopes

Transportation Services (IITS) and increase our revenues from

Transportation Services to commercial customers.

-- To continue to expand our customer base, increase revenues in every

business segment, continue to reduce production and operating costs,

and attempt to achieve profitability.

International Isotopes Inc.

Year Ended Dec. 31

2006 2007 Change $'s Change %

Sales of Products $4,469,538 $ 4,690,588 $221,050 5%

Gross Profit $2,006,823 $2,029,807 $22,984 1%

Total Operating

Expense $2,871,295 $3,645,549 $774,254 27%

Operating Loss

Before Other Expense ($864,472) ($1,615,742) $751,270 87%

Other Expense ($172,840) (103,313) $69,527 (41%)

Net Loss ($1,037,312) ($1,719,055) ($681,743) (65%)

Net (Loss) Per

Common Share ($0.00) ($0.01)

Weighted Ave. Sh.

Outstanding 211,984,394 238,939,638

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources. The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including the statement with respect to improving our financial performance; increasing our revenues; decreasing our operating expenses; realizing revenues from our FEP segment, and expanding our customer base. Information contained in such forward- looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance or achievements of International Isotopes, Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes, Inc.'s filings with the Securities and Exchange Commission at http://www.sec.gov, including our annual report on Form 10-KSB for the year ending December 31, 2007. Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

For More Information, Contact:

Steve Laflin, President and CEO

(208) 524-5300


'/>"/>
SOURCE International Isotopes Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. China Yingxia International Announces Soybean Milk Production Lines Acquisition
2. Infant formula must contain DHA omega-3 and AA omega-6, say international experts
3. The Top Ten Health Tips for International Travel
4. International Health Leaders Address Globalization and Academic Health Center Infrastructure
5. China Yingxia International Announces 2007 Fourth Quarter and Full Year Financial Results Conference Call
6. Murad Expands International Presence With Appointment of Danny Guez
7. International Eye Foundation Announces Partnership with Newport Creative Communications
8. China RuiTai International Holdings Retains CCG Elite for Investor Relations Services
9. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes
11. PRA International Announces New Office Opening in Mumbai
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... Arizona (PRWEB) , ... May 06, 2016 , ... ... moved domains to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis ... research and testing areas, which now include pillows, sheets, mattress toppers, bed frames, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. ... Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid ... Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology: